Korro Bio, Inc. ( (KRRO) ) has released its Q3 earnings. Here is a breakdown of the information Korro Bio, Inc. presented to its investors.

A live webcast of the presentation can be accessed on the "Events & Presentations" page in the Investor section of Korro’s website at www.korrobio.com. Following the presentation, a replay of the ...

Research and Development (R&D) Expenses: R&D expenses were $16.0 million for the three months ended September 30, 2024, as compared to $14.0 million for the same period in 2023. The increase was ...

CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA ...

RBC Capital raised the firm’s price target on Korro Bio (KRRO) to $105 from $95 and keeps an Outperform rating on the shares. The firm notes that RNA editing data from Wave Life Sciences (WVE ...

Korro is a developer of RNA-edited therapies also focused on treating AATD, via its lead candidate KRRO-110. During the 20 th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS ...

Korro Bio stock opened at $70.02 on Monday. Korro Bio has a fifty-two week low of $9.15 and a fifty-two week high of $98.00. The stock’s fifty day moving average is $43.72 and its two-hundred ...

Shares of NASDAQ KRRO opened at $77.00 on Thursday. Korro Bio has a 12-month low of $9.15 and a 12-month high of $98.00. The stock has a fifty day moving average price of $40.45 and a 200 day ...

Korro Bio, Inc. (NASDAQ:KRRO), a biotechnology company specializing in RNA editing, is making significant strides in the development of genetic medicines, particularly for Alpha-1 Antitrypsin ...

Clinical Advisory Board of lung and liver experts formed to support development of KRRO-110 CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a ...